Palmar plantar erythrodysesthesia natural history, complications, and prognosis: Difference between revisions

	Palmar plantar erythrodysesthesia Microchapters
Home
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Palmar plantar erythrodysesthesia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Palmar plantar erythrodysesthesia natural history, complications, and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia natural history, complications, and prognosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Palmar plantar erythrodysesthesia natural history, complications, and prognosis
CDC on Palmar plantar erythrodysesthesia natural history, complications, and prognosis
Palmar plantar erythrodysesthesia natural history, complications, and prognosis in the news
Blogs on Palmar plantar erythrodysesthesia natural history, complications, and prognosis
Directions to Hospitals Treating Palmar plantar erythrodysesthesia
Risk calculators and risk factors for Palmar plantar erythrodysesthesia natural history, complications, and prognosis

VisualWikitext

Revision as of 15:21, 26 June 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

OR

Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].

OR

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

Natural History, Complications, and Prognosis

Natural History

The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
The symptoms of (disease name) typically develop ___ years after exposure to ___.
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

Complications

Common complications of [disease name] include:
- [Complication 1]
- [Complication 2]
- [Complication 3]

Prognosis

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
[Subtype of disease/malignancy] is associated with the most favorable prognosis.
The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.

@@ Line 1: / Line 1: @@
+__NOTOC__
 {{Palmar plantar erythrodysesthesia}}
-{{CMG}}; '''Associate Editor(s)-in-Chief:''' Zain Fatiwala, M.D.
+{{CMG}}; {{AE}}
 ==Overview==
-Initially, the patient of Palmar Plantar Erythrosysesthesia experiences a sensation of numbness/tingling in the palms and soles. This progresses into a painful, tingling, symmetric, well-demarcated swelling with an erythematous plaques. It is followed by a phase of desquamation upon resolution. <ref name="urlAcral Erythema - Holland-Frei Cancer Medicine - NCBI Bookshelf2" />
+If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
+OR
+Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
+OR
+Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
+==Natural History, Complications, and Prognosis==
+===Natural History===
+*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
+*The symptoms of (disease name) typically develop ___ years after exposure to ___.
+*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
-==Natural History==
+===Complications===
-Initially, the patient of Palmar Plantar Erythrosysesthesia experiences a sensation of numbness/tingling in the palms and soles. This progresses into a painful, tingling, symmetric, well-demarcated swelling with an erythematous plaques. It is followed by a phase of desquamation upon resolution.<ref name="urlAcral Erythema - Holland-Frei Cancer Medicine - NCBI Bookshelf2">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK12891/ |title=Acral Erythema - Holland-Frei Cancer Medicine - NCBI Bookshelf |format= |work= |accessdate=}}</ref>
+*Common complications of [disease name] include:
+**[Complication 1]
+**[Complication 2]
+**[Complication 3]
-One of the complications associated with PPE is loss of fingerprints. It is documented in a patient who was treated with capecitabine and detained at an airport while travelling because of lack of finger prints.<ref name="pmid19470576">{{cite journal| author=Wong M, Choo SP, Tan EH| title=Travel warning with capecitabine. | journal=Ann Oncol | year= 2009 | volume= 20 | issue= 7 | pages= 1281 | pmid=19470576 | doi=10.1093/annonc/mdp278 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19470576  }}</ref>
+===Prognosis===
+*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
+*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
+*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
+*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
+*The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
-==Prognosis==
-PPE variably recurs with resumption of chemotherapy. Long-term chemotherapy may also result in reversible [[palmoplantar keratoderma]]. Symptoms resolve 1-2 weeks after cessation of chemotherapy (Apisarnthanarax and Duvic 2003).
 ==References==
 {{reflist|3}}